Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Oct 19;19(1):98.
doi: 10.1186/s10194-018-0928-1.

Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial

Licia Grazzi  1   2 , Cristina Tassorelli  3   4 , Marina de Tommaso  5 , Giulia Pierangeli  6 , Paolo Martelletti  7 , Innocenzo Rainero  8 , Pierangelo Geppetti  9 , Anna Ambrosini  10 , Paola Sarchielli  11 , Eric Liebler  12 , Piero Barbanti  13 ; PRESTO Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial

Licia Grazzi et al. J Headache Pain. .

Erratum in

Abstract

Background: The PRESTO study of non-invasive vagus nerve stimulation (nVNS; gammaCore®) featured key primary and secondary end points recommended by the International Headache Society to provide Class I evidence that for patients with an episodic migraine, nVNS significantly increases the probability of having mild pain or being pain-free 2 h post stimulation. Here, we examined additional data from PRESTO to provide further insights into the practical utility of nVNS by evaluating its ability to consistently deliver clinically meaningful improvements in pain intensity while reducing the need for rescue medication.

Methods: Patients recorded pain intensity for treated migraine attacks on a 4-point scale. Data were examined to compare nVNS and sham with regard to the percentage of patients who benefited by at least 1 point in pain intensity. We also assessed the percentage of attacks that required rescue medication and pain-free rates stratified by pain intensity at treatment initiation.

Results: A significantly higher percentage of patients who used acute nVNS treatment (n = 120) vs sham (n = 123) reported a ≥ 1-point decrease in pain intensity at 30 min (nVNS, 32.2%; sham, 18.5%; P = 0.020), 60 min (nVNS, 38.8%; sham, 24.0%; P = 0.017), and 120 min (nVNS, 46.8%; sham, 26.2%; P = 0.002) after the first attack. Similar significant results were seen when assessing the benefit in all attacks. The proportion of patients who did not require rescue medication was significantly higher with nVNS than with sham for the first attack (nVNS, 59.3%; sham, 41.9%; P = 0.013) and all attacks (nVNS, 52.3%; sham, 37.3%; P = 0.008). When initial pain intensity was mild, the percentage of patients with no pain after treatment was significantly higher with nVNS than with sham at 60 min (all attacks: nVNS, 37.0%; sham, 21.2%; P = 0.025) and 120 min (first attack: nVNS, 50.0%; sham, 25.0%; P = 0.018; all attacks: nVNS, 46.7%; sham, 30.1%; P = 0.037).

Conclusions: This post hoc analysis demonstrated that acute nVNS treatment quickly and consistently reduced pain intensity while decreasing rescue medication use. These clinical benefits provide guidance in the optimal use of nVNS in everyday practice, which can potentially reduce use of acute pharmacologic medications and their associated adverse events.

Trial registration: ClinicalTrials.gov identifier: NCT02686034 .

Keywords: Migraine; Neuromodulation; Pain intensity; Post hoc analysis; Rescue medication; Vagus nerve stimulation.

PubMed Disclaimer

Conflict of interest statement

L. Grazzi has received consultancy and advisory fees from Allergan S.p.A. and electroCore, Inc. C. Tassorelli has consulted for Allergan S.p.A.; electroCore, Inc.; Eli Lilly and Company; and Novartis AG and has received research grants from the European Commission and the Italian Ministry of Health. She is also a principal investigator or collaborator for RCTs sponsored by Alder BioPharmaceuticals Inc.; Eli Lilly and Company; and Teva Pharmaceutical Industries Ltd. M. de Tommaso has received advisory fees from Allergan S.p.A.; Neopharmed; and Pfizer Inc. G. Pierangeli has nothing to disclose. P. Martelletti has received research grants, advisory board fees, or travel fees from ACRAF; Allergan S.p.A.; Amgen Inc.; electroCore, Inc.; Novartis AG; and Teva Pharmaceutical Industries Ltd. I. Rainero has received consultancy fees from electroCore, Inc., and Mylan N.V. and research grants from the European Commission -- Horizon 2020. He is also a principal investigator for RCTs sponsored by Axovant Sciences Ltd. and TauRx Pharmaceuticals Ltd. P. Geppetti has received consultancy fees from Allergan S.p.A.; electroCore, Inc.; Evidera; Novartis AG; Pfizer Inc.; and Sanofi S.p.A. and research grants from Chiesi Farmaceutici S.p.A. He is also a principal investigator for RCTs sponsored by Eli Lilly and Company; Novartis AG; and Teva Pharmaceutical Industries Ltd. A. Ambrosini has received consultancy fees from Almirall, S.A., and travel grants from Allergan S.p.A.; Almirall, S.A.; and Novartis AG. P. Sarchielli has received clinical study fees from Allergan S.p.A. E. Liebler is an employee of electroCore, Inc., and receives stock ownership. P. Barbanti has received consultancy fees from Allergan S.p.A.; electroCore, Inc.; Janssen Pharmaceuticals, Inc.; Lusofarmaco; and Visufarma and advisory fees from Abbott Laboratories and Merck & Co., Inc.

Figures

Fig. 1
Fig. 1
The Non-invasive Vagus Nerve Stimulation Device. Note: A previous model of the nVNS device was used by patients in the PRospectivE Study of nVNS for the acute Treatment Of migraine (PRESTO) trial. Image provided courtesy of electroCore, Inc. Abbreviation: nVNS, non-invasive vagus nerve stimulation
Fig. 2
Fig. 2
PRESTO Treatment Paradigm. Abbreviations: L, left; nVNS, non-invasive vagus nerve stimulation; R, right; Stim, stimulation
Fig. 3
Fig. 3
≥1-Point Reduction in Pain Intensity at 30, 60, and 120 Minutes for (a) First Attack and (b) All Attacks. Models are adjusted for the patients' baseline pain score, use of preventive therapies, and presence of aura; data for number of patients are unadjusted numbers. Abbreviation: nVNS, non-invasive vagus nerve stimulation
Fig. 4
Fig. 4
Rescue Medication Use. Models are adjusted for the patients’ baseline pain score, use of preventive therapies, and presence of aura; data for number of patients are unadjusted numbers. Abbreviation: nVNS, non-invasive vagus nerve stimulation
Fig. 5
Fig. 5
Pain-free Rates at 30, 60, and 120 Minutes for (a) First Attack and (b) All Attacks. Abbreviation: nVNS, non-invasive vagus nerve stimulation
See this image and copyright information in PMC

References

    1. Barbanti P, Grazzi L, Egeo G, Padovan AM, Liebler E, Bussone G. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. J Headache Pain. 2015;16:61. doi: 10.1186/s10194-015-0542-4. - DOI - PMC - PubMed
    1. Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA. Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia. 2014;34(12):986–993. doi: 10.1177/0333102414524494. - DOI - PubMed
    1. Kinfe TM, Pintea B, Muhammad S, Zaremba S, Roeske S, Simon BJ, Vatter H. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study. J Headache Pain. 2015;16:101. doi: 10.1186/s10194-015-0582-9. - DOI - PMC - PubMed
    1. Tassorelli C, Grazzi L, de Tommaso M, Pierangeli G, Martelletti P, Rainero I, Dorlas S, Geppetti P, Ambrosini A, Sarchielli P, Liebler E, Barbanti P, Group PS Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology. 2018;91(4):e364–e373. doi: 10.1212/WNL.0000000000005857. - DOI - PMC - PubMed
    1. Buse DC, Serrano D, Reed ML, Kori SH, Cunanan CM, Adams AM, Lipton RB. Adding additional acute medications to a triptan regimen for migraine and observed changes in headache-related disability: results from the American migraine prevalence and prevention (AMPP) study. Headache. 2015;55(6):825–839. doi: 10.1111/head.12556. - DOI - PubMed

Publication types

Associated data